Gregory Y H Lip

National Yang Ming University, T’ai-pei, Taipei, Taiwan

Are you Gregory Y H Lip?

Claim your profile

Publications (848)4520.5 Total impact

  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Peroxiredoxin (PRDX) and Thioredoxin (TRX) are antioxidant proteins that control cellular signalling and redox balance, although their response to exercise is unknown. This study aimed to assess key aspects of the PRDX-TRX redox cycle in response to three different modes of exercise. Methods: Healthy males (n=10, mean ± SD: age 22 ± 3 yrs) undertook three exercise trials on separate days: two steady-state cycling trials at a moderate (60% MAX; 27 min, MOD) and high (80% MAX; 20 min, HIGH) intensity, and a low volume high intensity interval training trial (10×1 min 90% MAX, LV-HIIT). Peripheral blood mononuclear cells (PBMCs) were assessed for TRX-1 and over-oxidised PRDX (isoforms I-IV) protein expression before, during and 30 minutes following exercise (post+30). The activities of TRX reductase (TRX-R) and the NF-κB p65 subunit were also assessed. Results: TRX-1 increased during exercise in all trials (MOD +84.5%; HIGH +64.1%; LV-HIIT +205.7%; p<.05), whereas over-oxidised PRDX increased during HIGH only (MOD -28.7%; HIGH +202.9%; LV-HIIT -22.7%; p<.05). TRX-R and NF-κB p65 activity increased during exercise in all trials, with the greatest response in TRX-R activity seen in HIGH (p<.05). Discussion: All trials stimulated a transient increase in TRX-1 protein expression during exercise. Only HIGH induced a transient over-oxidation of PRDX, alongside the greatest change in TRX-R activity. Future studies are needed to clarify the significance of heightened peroxide exposure during continuous high intensity exercise and the mechanisms of PRDX-regulatory control.
    Free Radical Research 12/2014; · 3.28 Impact Factor
  • Keitaro Senoo, Deirdre A Lane, Gregory Y H Lip
    [Show abstract] [Hide abstract]
    ABSTRACT: Current clinical guidelines recommend that risk stratification for ischaemic stroke in patients with nonvalvular AF (NVAF) should be performed using the CHA2DS2-VASc score (Congestive heart failure, Hypertension, Age≥75years [double], Diabetes mellitus, previous thromboembolism [double], Vascular disease, Age 65-74years, and female gender) to aid decision making for antithrombotic treatment, with a preference for Non-Vitamin K Oral Anticoagulants (NOACs) in those with CHA2DS2-VASc score ≥1. However, CHA2DS2-VASc score is not recommended in the 2014 Japanese Circulation Society (JCS) guidelines for patients with NVAF. To assess the impact of the JCS approach to stroke prevention in AF, and model the impact of using a CHA2DS2-VASc based 2-step decision making strategy, we calculated the incidence of ischaemic stroke in NVAF patients without OAC on basis of the CHADS2 and CHA2DS2-VASc scores using published Japanese data, and estimated the preventable number of stroke events. Using a CHA2DS2-VASc-based approach, the potential annual stroke events based on the estimated total number of NVAF patients in Japan was 889,000, as follows: 4369 for dabigatran 150mg, 6049 for dabigatran 110mg, 5918 for rivaroxaban (intention-to-treat; ITT), 5302 for apixaban, 5843 for edoxaban 60mg (ITT), and 7598 for edoxaban 30mg (ITT), respectively. Using a CHADS2 score-based approach, the number of potential stroke events was much greater for each agent. Our modelling analysis has shown that when considering antithrombotic treatment for Japanese NVAF patients, using a CHA2DS2-VASc-based approach would allow greater opportunities for stroke prevention. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
    International Journal of Cardiology 12/2014; 181C:247-254. · 6.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study sought to investigate the relative efficacy and safety of non-vitamin K oral anticoagulants (NOACs) for the treatment of venous thromboembolism (VTE) in cancer patients. A systematic search of the PubMed, EMBASE, and ClinicalTrials.gov databases identified all multicentre, randomised phase III trials investigating the initial use of NOAC against a vitamin K antagonist (VKA) together with subcutaneous heparin or low molecular weight heparin (upstart) for treatment of VTE. Outcomes of interest were recurrent VTE (deep venous thrombosis or pulmonary embolism), and clinically relevant bleeding. Four randomised controlled phase III trials were included, comprising a total of 19,060 patients randomised to either NOAC or VKA. For patients with active cancer (N = 759), the analysis on the efficacy outcomes demonstrated a trend in favour of NOAC (OR 0.56, 95% CI 0.28-1.13). Similar, analyses on the safety outcomes comparing NOAC to VKA and enoxaparin demonstrated a trend in favour of NOAC (OR 0.88, 95% CI 0.57-1.35). Point estimates of the effect size suggest an important estimated beneficial effect of NOAC in the treatment of VTE in cancer, in terms of efficacy and safety, but given the small numbers of patients with cancer in the randomised trials, statistical significance was not achieved.
    PLoS ONE 12/2014; 9(12):e114445. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Rheumatoid arthritis (RA) is a chronic inflammatory condition with increased all-cause and cardiovascular mortality. Accumulating evidence indicates that the immune and autonomic nervous systems (ANS) are major contributors to the pathogenesis of cardiovascular disease. We performed the first systematic literature review to determine the prevalence and nature of ANS dysfunction in RA and whether there is a causal relationship between inflammation and ANS function. Methods Electronic databases (Medline, Central and Cochrane Library) were searched for studies of RA patients where autonomic function was assessed. Results Forty studies in total were included. ANS function was assessed by clinical cardiovascular reflex tests (CCTs)(n=18), heart rate variability (HRV)(n=15), catecholamines (n=5), biomarkers of sympathetic activity (n=5), sympathetic skin responses (n=5), cardiac baroreflex sensitivity (cBRS) (n=2) and pupillary light reflexes (n=2). 9 small studies reported a ~60% (median, range 20-86%) prevalence of ANS dysfunction (defined by abnormal CCTs) in RA. 73% of studies (n=27/37) reported at least one abnormality in ANS function: parasympathetic dysfunction (n=20/26, 77%), sympathetic dysfunction (n=16/30, 53%) or reduced cBRS (n=1/2, 50%). An association between increased inflammation and ANS dysfunction was found (n=7/19, 37%) although causal relationships could not be elucidated from the studies available to date. Conclusions ANS dysfunction is prevalent in ~60% of RA patients. The main pattern of dysfunction is impairment of cardiovascular reflexes and altered HRV indicative of reduced cardiac parasympathetic (strong evidence) and elevated cardiac sympathetic activity (limited evidence). The literature to date is underpowered to determine causal relationships between inflammation and ANS dysfunction in RA.
    Seminars in Arthritis and Rheumatism 12/2014; · 3.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Atrial fibrillation and heart failure often coexist, causing substantial cardiovascular morbidity and mortality. β blockers are indicated in patients with symptomatic heart failure with reduced ejection fraction; however, the efficacy of these drugs in patients with concomitant atrial fibrillation is uncertain. We therefore meta-analysed individual-patient data to assess the efficacy of β blockers in patients with heart failure and sinus rhythm compared with atrial fibrillation. Methods We extracted individual-patient data from ten randomised controlled trials of the comparison of β blockers versus placebo in heart failure. The presence of sinus rhythm or atrial fibrillation was ascertained from the baseline electrocardiograph. The primary outcome was all-cause mortality. Analysis was by intention to treat. Outcome data were meta-analysed with an adjusted Cox proportional hazards regression. The study is registered with Clinicaltrials.gov, number NCT0083244, and PROSPERO, number CRD42014010012. Findings 18 254 patients were assessed, and of these 13 946 (76%) had sinus rhythm and 3066 (17%) had atrial fibrillation at baseline. Crude death rates over a mean follow-up of 1·5 years (SD 1·1) were 16% (2237 of 13 945) in patients with sinus rhythm and 21% (633 of 3064) in patients with atrial fibrillation. β-blocker therapy led to a significant reduction in all-cause mortality in patients with sinus rhythm (hazard ratio 0·73, 0·67–0·80; p<0·001), but not in patients with atrial fibrillation (0·97, 0·83–1·14; p=0·73), with a significant p value for interaction of baseline rhythm (p=0·002). The lack of efficacy for the primary outcome was noted in all subgroups of atrial fibrillation, including age, sex, left ventricular ejection fraction, New York Heart Association class, heart rate, and baseline medical therapy. Interpretation Based on our findings, β blockers should not be used preferentially over other rate-control medications and not regarded as standard therapy to improve prognosis in patients with concomitant heart failure and atrial fibrillation. Funding Menarini Farmaceutica Internazionale (administrative support grant).
    The Lancet 12/2014; · 39.21 Impact Factor
  • European Heart Journal 12/2014; · 14.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both ‘new starters’ on dabigatran and ‘switchers’ to dabigatran from warfarin. Methods We identified in nationwide Danish registries 2,398 patients with atrial fibrillation and a history of stroke/TIA, making a first-time purchase of dabigatran 110mg bid (D110) and 150mg bid (D150). Patients were categorized as either vitamin K antagonist (VKA) naïve or experienced. Warfarin controls were identified using a complete (for VKA-naïve dabigatran patients) or matched sampling approach (for VKA-experienced dabigatran patients). Subjects were followed for an average of 12.6 months for stroke and transient ischemic attacks. Confounder-adjusted Cox regression models were used to compare event rates between treatments. Results Among patients with a history of stroke/ transient ischemic attack and prior VKA experience, switching to dabigatran was associated with an increased stroke/ transient ischemic attack rate for both dabigatran doses compared to continuing on warfarin (D110 hazard ratio [HR] 1.99, 95% confidence interval [CI]: 1.42-2.78; D150 HR 2.34, 95% CI: 1.60-3.41). Among prior stroke/ transient ischemic attack patients who were new starters on dabigatran or warfarin, the rate of stroke/ transient ischemic attack for both doses of dabigatran was similar to or lower than warfarin (D110 HR 0.64, 95% CI: 0.50-0.80; D150 HR 0.92, 95% CI: 0.73-1.15). Conclusions In this register-based study, VKA-experienced patients with a history of stroke or transient ischemic attack who switched to dabigatran therapy had an increased rate of stroke compared to patients persisting with warfarin therapy.
    The American Journal of Medicine 12/2014; · 5.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: New oral anticoagulants require dosing adjustment according to renal function. We aimed to determine discordance in hypothetical recommended dosing of these drugs using different estimated glomerular filtration rate equations in patients with atrial fibrillation.
    Revista Espanola de Cardiologia 11/2014; · 3.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are limited prospective data evaluating the role of urinary F2-IsoP and NOX2 as predictive markers in AF. The aim of this study was to analyse the role of urinary prostaglandin PGF2alpha (8-iso-PGF2α) and NOX2, markers of systemic oxidative stress, in predicting cardiovascular (CV) events and mortality in anticoagulated non-valvular atrial fibrillation (AF) patients. This was a prospective study including 1,002 anticoagulated AF patients, followed for a median time of 25.7 months (interquartile range: 14.8-50.9). All major CV events, CV deaths and all-cause deaths were considered as primary outcomes of the study. CV events included fatal/nonfatal ischaemic stroke, fatal/nonfatal myocardial infarction (MI), cardiac revascularisation and transient ischaemic attack (TIA). Oxidative stress biomarkers, such as urinary 8-iso-PGF2α and serum sNOX2-dp, a marker of NOX2 activation, were measured. A CV event occurred in 125 patients (12.5 %); 78 CV deaths and 31 non-CV deaths were registered. 8-iso-PGF2α and sNOX2-dp were correlated (Rs=0.765 p< 0.001). A significant increased cumulative incidence of CV events and CV deaths was observed across tertiles for 8-iso-PGF2α and sNOX2-dp. An increased rate of all-cause death was observed across tertiles of urinary 8-iso-PGF2α. In Cox or Fine and Gray models, 8-iso-PGF2α predicted CV events and CV and non-CV deaths. The addition of tertiles of 8-iso-PGF2α to CHA2DS2-VASc score improved ROC curves for each outcome and NRI for CV events (0.24 [0.06-0.53] p=0.0067). The study shows that in AF patients 8-iso-PGF2α and NOX2 levels are predictive of CV events and total mortality. F2-IsoP may complement conventional risk factors in prediction of CV events.
    Thrombosis and Haemostasis 11/2014; 113(2). · 5.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Catheter ablation (CA) of atrial fibrillation (AF) is associated with inflammatory response, endothelial damage and with increased risk of thrombosis. However, whether these processes differ in peripheral and cardiac circulation is unknown.
    PLoS ONE 11/2014; 9(11):e111760. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A meta-analysis was performed to evaluate the risk of major bleeding with the use of New Oral Anticoagulants (NOACs).Methods Randomized controlled trials (RCTs) comparing NOACs (rivaroxaban, dabigatran, apixaban, edoxaban and darexaban) with comparators were selected.ResultsFifty trials included 155,537 patients. Pooled analysis of all NOACs for all indications together demonstrated no significant difference between NOACs and comparators for risk of major bleeding (odds ratio [OR] 0.93, 95% CI 0.79–1.09). Pooled analysis also showed that NOACs caused significantly less major bleeding compared to vitamin K antagonists (VKA) (0.77, 0.64–0.91). The analysis for individual NOACs showed risk of major bleeding were not different with rivaroxaban, apixaban or dabigatran compared to pharmacologically active comparators or VKA. Indication specific analysis showed that NOACs were associated with significantly higher major bleeding after hip surgery (1.43, 1.02–1.99), in patients with acute coronary syndrome (ACS), (compared against placebo) (2.89, 2.01–4.14), and for medically ill patients (2.79, 1.69–4.60). For the treatment of acute venous thromboembolism (VTE) or pulmonary embolism (PE), NOACs were associated with significantly less bleeding (0.63, 0.44–0.90). No significant difference was found between NOACs and comparators in treatment of atrial fibrillation and for extended treatment of VTE.Conclusions Risk of major bleeding with new oral anticoagulants varies with their indication for use. New agents may be associated with comparatively less major bleeding compared to VKA. NOAC may increase the risk of major bleeding after hip surgery, ACS and acute medically ill patients; but may be associated with less bleeding in treatment of acute VTE/PE.
    International Journal of Cardiology 11/2014; · 6.18 Impact Factor
  • Mikhail S. Dzeshka, Gregory Y.H. Lip
    [Show abstract] [Hide abstract]
    ABSTRACT: Atrial fibrillation (AF) confers increased risk of stroke and other thromboembolic events, and oral anticoagulation therefore is the essential part of AF management to reduce the risk of this complication. Until recently, the vitamin K antagonists (VKAs, e.g. warfarin) were the only oral anticoagulants available, acting by decreased synthesis of vitamin K-dependent coagulation factors (II, VI, IX, and X). The VKAs had many limitations: delayed onset and prolonged offset of action, variability of anticoagulant effect among patients, multiple food and drug interactions affecting pharmacological properties of warfarin, narrow therapeutic window, obligatory regular laboratory control, which all made warfarin ‘inconvenient’ both for patients and clinicians. The limitations of VKAs led to development of new class of drugs collectively defined as non-VKA oral anticoagulants (NOACs), which included direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, edoxaban). The NOACs avoid many of the VKA drawbacks. In this review, we will focus on the current evidence justifying use of NOACs in non-valvular AF.
    Trends in Cardiovascular Medicine 10/2014; · 2.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A new scoring system, the anticoagulation and risk factors in atrial fibrillation (ATRIA) score, was proposed for risk stratification in patients with atrial fibrillation (AF). Whether the ATRIA scheme can adequately identify patients who are at low risk of ischemic stroke remains unknown.
    Journal of the American College of Cardiology 10/2014; 64(16):1658-65. · 15.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Even 10 years after the first appearance in the literature of articles reporting on the management of patients on oral anticoagulation (OAC) undergoing percutaneous coronary intervention with stent (PCI-S), this issue is still controversial. Nonetheless, some guidance for the everyday management of this patient subset, accounting for about 5-8 % of all patients referred for PCI-S, has been developed. In general, a period of triple therapy (TT) of OAC, with either vitamin K-antagonists (VKA) or non-vitamin K-antagonist oral anticoagulants (NOAC), aspirin, and clopidogrel is warranted, followed by the combination of OAC, and a single antiplatelet agent for up to 12 months, and then OAC alone. The duration of the initial period of TT is dependent on the individual risk of thromboembolism, and bleeding, as well as the clinical context in which PCI-S is performed (elective vs acute coronary syndrome), and the type of stent implanted (bare-metal vs drug-eluting). In this article, we aim to provide a comprehensive, at-a-glance, overview of the management strategies, which are currently suggested for the peri-procedural, medium-term, and long-term periods following PCI-S in OAC patients. While acknowledging that most of the evidence has been obtained from patients on OAC because of atrial fibrillation, and with warfarin being the most frequently used VKA, we refer in this overview to the whole population of OAC patients undergoing PCI-S. We refer to the whole population of patients on OAC undergoing PCI-S also when OAC is carried out with NOAC rather than VKA, pointing out, when appropriate, the particular management issues.
    Thrombosis and Haemostasis 10/2014; 112(6). · 5.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Renal impairment is associated with poor prognosis in the setting of atrial fibrillation (AF). While AF catheter ablation is an effective treatment modality for AF burden reduction and improvement of symptoms, changes in renal function after catheter ablation and their association with rhythm outcome have not been studied in a large contemporary AF ablation cohort.
    Heart (British Cardiac Society) 10/2014; · 6.02 Impact Factor
  • Y C Lau, A Blann, G Y H Lip
    [Show abstract] [Hide abstract]
    ABSTRACT: In atrial fibrillation (AF), oral anticoagulant(OAC) is the mainstay treatment in prevention of stroke. However, the various OAC confers one with different level of protection against thrombosis and bleeding risk, possibly due to different effect on fibrin clot structure. Coagulation and clot lysis can be assessed by Thrombelastography(TEG).
    Europace 10/2014; 16 Suppl 3:iii8. · 3.05 Impact Factor
  • Article: The reply.
    The American journal of medicine. 10/2014; 127(10):e21.
  • K L Harvey, D A Lane, G Y H Lip
    [Show abstract] [Hide abstract]
    ABSTRACT: Atrial tachyarrhythmias (ATA) are associated with increased risk of stroke. Implantable cardiac devices (ICDs) can detect and store these arrhythmias. This study investigated the role of stroke risk stratification tools, CHADS2 and CHA2DS2-VASc, in predicting new-onset ATAs in the ICD population.
    Europace 10/2014; 16 Suppl 3:iii14. · 3.05 Impact Factor
  • Source
    Andrew D. Blann, Gregory Y.H. Lip
    Journal of the American College of Cardiology 09/2014; 64(11):1140–1142. · 15.34 Impact Factor

Publication Stats

17k Citations
4,520.50 Total Impact Points

Institutions

  • 2014
    • National Yang Ming University
      • School of Medicine
      T’ai-pei, Taipei, Taiwan
  • 2013–2014
    • University of Belgrade
      • Chair of Pharmacology, Clinical Pharmacology and Toxicology
      Beograd, Central Serbia, Serbia
    • University of Turku
      Turku, Province of Western Finland, Finland
    • Aston University
      • School of Life and Health Sciences
      Birmingham, England, United Kingdom
    • University of Groningen
      • Department of Cardiology
      Groningen, Province of Groningen, Netherlands
    • Wiener Krankenanstaltenverbund
      Wien, Vienna, Austria
    • Università degli Studi G. d'Annunzio Chieti e Pescara
      Chieta, Abruzzo, Italy
  • 2012–2014
    • Aalborg University
      • • Department of Clinical Medicine
      • • Faculty of Medicine
      Ålborg, North Denmark, Denmark
    • Ludwig-Maximilians-University of Munich
      München, Bavaria, Germany
    • Maastricht University
      • Cardiologie
      Maastricht, Provincie Limburg, Netherlands
    • University of Iowa
      Iowa City, Iowa, United States
    • University of Bologna
      • Institute of Cardiology
      Bologna, Emilia-Romagna, Italy
    • Karolinska Institutet
      • Institutionen för klinisk forskning och utbildning, Södersjukhuset
      Stockholm, Stockholm, Sweden
    • McMaster University
      • Department of Medicine
      Hamilton, Ontario, Canada
  • 2012–2013
    • Chinese PLA General Hospital (301 Hospital)
      Peping, Beijing, China
    • University of Murcia
      Murcia, Murcia, Spain
  • 2008–2013
    • Hospital Universitario Virgen de la Arrixaca
      • Departamento de Cardiología
      Murcia, Murcia, Spain
    • University of Bristol
      Bristol, England, United Kingdom
  • 2000–2013
    • University of Birmingham
      • • Centre for Cardiovascular Sciences
      • • Department of Primary Care Clinical Sciences
      • • School of Psychology
      Birmingham, England, United Kingdom
  • 1996–2013
    • Birmingham City University
      Birmingham, England, United Kingdom
  • 1994–2013
    • University Hospitals Birmingham NHS Foundation Trust
      • Department of Medicine
      Birmingham, ENG, United Kingdom
  • 2011–2012
    • Klinički centar Srbije
      • Institute for Cardiovascular Diseases
      Beograd, Central Serbia, Serbia
    • East Coast Community Healthcare CIC
      Beccles, England, United Kingdom
    • Medical University of Vienna
      Wien, Vienna, Austria
    • Aarhus University Hospital
      • Department of Cardiology
      Århus, Central Jutland, Denmark
    • Azienda Ospedaliero Universitaria Careggi
      • Department of Heart and Vessels
      Firenzuola, Tuscany, Italy
    • Copenhagen University Hospital Gentofte
      • Department of Dermato-Allergology
      Hellebæk, Capital Region, Denmark
  • 2010–2012
    • Turku University Hospital
      • Turku PET Centre
      Turku, Province of Western Finland, Finland
    • Princess Alexandra Hospital (Queensland Health)
      Brisbane, Queensland, Australia
    • Medicines and Healthcare products Regulatory Agency (MHRA)
      Londinium, England, United Kingdom
    • Centre Hospitalier Universitaire de Tours
      Tours, Centre, France
  • 2004–2012
    • Hospital General Universitario de Alicante
      • Departamento de Cardiología
      Alicante, Valencia, Spain
  • 2003–2012
    • Sandwell and West Birmingham Hospitals NHS Trust
      Birmingham, England, United Kingdom
    • Queen Elizabeth Hospital Birmingham
      Birmingham, England, United Kingdom
    • Aix-Marseille Université
      Marsiglia, Provence-Alpes-Côte d'Azur, France
  • 2007–2011
    • The Bracton Centre, Oxleas NHS Trust
      Дартфорде, England, United Kingdom
    • St George's, University of London
      • Division of Clinical Sciences
      Londinium, England, United Kingdom
    • Royal College of Physicians
      Londinium, England, United Kingdom
    • Taunton and Somerset NHS Foundation Trust
      Taunton, England, United Kingdom
    • East Sussex Healthcare NHS Trust
      Eastbourne, England, United Kingdom
    • King's College London
      • Cardiovascular Division
      London, ENG, United Kingdom
    • Hospital General Universitario de Elche
      Elche, Valencia, Spain
  • 2008–2010
    • Ospedale Maggiore Carlo Alberto Pizzardi di Bologna
      • Department of Cardiology
      Bolonia, Emilia-Romagna, Italy
  • 2009
    • University Hospitals Coventry and Warwickshire NHS Trust
      • Department of Cardiology
      Coventry, England, United Kingdom
    • AstraZeneca
      Tukholma, Stockholm, Sweden
  • 2003–2009
    • WWF United Kingdom
      Londinium, England, United Kingdom
  • 2006
    • University of California, San Diego
      • Moores Cancer Center/Oncology
      San Diego, California, United States
  • 2005
    • Hamilton Health Sciences
      Hamilton, Ontario, Canada
    • Otto-von-Guericke-Universität Magdeburg
      • Clinic for Cardiology, Angiology and Pneumology
      Magdeburg, Saxony-Anhalt, Germany
  • 2002
    • University of Vienna
      Wien, Vienna, Austria